Cancer and Tumor Biomarker-based Assay Market Size & Growth Forecast 2027–2036, By Segments (End Use, Cancer Type, Biomarker Type), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Jump to Content
Market Size and Growth Outlook
Cancer and Tumor Biomarker-based Assay Market size was valued at USD 12.93 billion in 2026 and is anticipated to grow at a 10.92% CAGR from 2027 to 2036, attaining USD 36.45 billion by 2036. The industry revenue for 2027 is assessed at USD 14.15 billion.
Get more details on this report
Request Free Sample ReportCancer and Tumor Biomarker-based Assay Market Intelligence Snapshot
Regional Market Dynamics
- North America accounted for 44.1% of the market in 2026, supported by advanced oncology research, established diagnostic infrastructure, precision medicine adoption, and increasing use of biomarker assays for treatment selection and disease monitoring.
- Asia Pacific is the fastest-growing region, driven by rising cancer incidence, expanding oncology services, improved laboratory infrastructure, and increasing adoption of molecular diagnostics and precision medicine for earlier, more targeted cancer care.
Segment Momentum
- Hospitals and cancer centers accounted for 47% of the market in 2026, supported by oncology expertise, advanced diagnostic infrastructure, and growing integration of biomarker assays into clinical workflows.
- Breast cancer held a 25.3% share in 2026 and is projected to grow fastest, driven by increasing biomarker testing for tumor characterization, personalized treatment selection, and response assessment.
Market Expansion Drivers
- Rising demand for early cancer detection and personalized medicine.
- Expansion of biopharmaceutical R&D and clinical diagnostics.
- Technological innovations in biomarker assays and high-throughput testing.
Leading Market Participants
- Major players in the cancer and tumor biomarker-based assay market include Roche (Switzerland), Thermo Fisher Scientific (USA), Agilent Technologies (USA), Abbott (USA), Bio-Rad Laboratories (USA), Qiagen (Netherlands), Illumina (USA), Siemens Healthineers (Germany), Becton Dickinson (USA), Merck KGaA (Germany).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 12.93 billion
- 2027 Estimated Market Size: USD 14.15 billion
- Projected Market Size: USD 36.45 billion by 2036
- Growth Forecast: 10.92% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: End Use (Hospitals and Cancer Centers) | Cancer Type (Breast Cancer) | Biomarker Type (Genetic / Genomic Biomarkers)
- Emerging Opportunity Segment: End Use (Hospitals and Cancer Centers) | Cancer Type (Breast Cancer) | Biomarker Type (Genetic / Genomic Biomarkers)
Market Growth Drivers and Industry Trends
Rising demand for early cancer detection and personalized medicine
Rising demand for early cancer detection and personalized medicine is driving the adoption of biomarker-based assays that can provide more precise insights into disease presence, progression, and treatment response. Biomarkers can support the identification of molecular characteristics associated with specific cancers, enabling clinicians to refine diagnostic and therapeutic strategies. Growing emphasis on individualized treatment pathways is further encouraging the use of biomarker testing as healthcare systems seek more targeted approaches to cancer management and improved clinical decision-making.
Expansion of biopharmaceutical R&D and clinical diagnostics
Expansion of biopharmaceutical research and clinical diagnostics is supporting demand for cancer and tumor biomarker-based assays across drug discovery, clinical development, and routine disease assessment. Biomarker testing plays an important role in identifying suitable patient populations, evaluating therapeutic responses, and understanding disease mechanisms during the development of targeted treatments. Increasing collaboration between research and diagnostic workflows is also strengthening the role of biomarker assays in translating molecular discoveries into clinically applicable cancer testing solutions.
Technological innovations in biomarker assays and high-throughput testing
Technological innovations in biomarker assays and high-throughput testing are improving the ability to analyze complex biological samples with greater sensitivity, specificity, and workflow efficiency. Advances in molecular detection, multiplex analysis, automation, and data interpretation are enabling broader evaluation of tumor characteristics while reducing operational complexity. These developments are expanding the practical application of biomarker-based testing across research and clinical settings and supporting the integration of more comprehensive molecular information into cancer diagnosis and treatment planning.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising demand for early cancer detection and personalized medicine | 4% | Short term (≤ 2 yrs) | North America; Europe; Spillover: Asia Pacific | Medium | Fast |
| Expansion of biopharmaceutical R&D and clinical diagnostics | 3.5% | Medium term (2–5 yrs) | North America; Asia Pacific; Spillover: Europe | Medium | Moderate |
| Technological innovations in biomarker assays and high-throughput testing | 3% | Long term (5+ yrs) | Europe; North America; Spillover: Asia Pacific | Low | Moderate |
Explore Growth Opportunities
Request Free Sample ReportRegional Demand Dynamics
North America (Largest Region)
North America held the largest share of 44.1% share in 2026 in the cancer and tumor biomarker-based assay market, driven by advanced oncology research capabilities, established diagnostic infrastructure, and increasing adoption of precision medicine approaches. Healthcare providers and research institutions are increasingly using biomarker-based assays to support early cancer detection, disease classification, treatment selection, and therapy monitoring. Strong clinical research activity and growing integration of molecular diagnostics into oncology workflows are supporting demand for sophisticated assay technologies. Increasing awareness of personalized treatment strategies and continued development of targeted therapies are also expanding the role of biomarker testing across a broad range of tumor types.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is projected to register the fastest growth in the cancer and tumor biomarker-based assay market as healthcare infrastructure improves and demand for advanced cancer diagnostics increases. Rising cancer incidence, expanding access to specialized oncology services, and greater awareness of early detection are encouraging healthcare systems to strengthen molecular testing capabilities. Investments in laboratory infrastructure and the adoption of precision medicine are creating opportunities for broader use of biomarker assays in hospitals and diagnostic centers. Growing research activity and increasing availability of advanced diagnostic technologies are further supporting regional expansion as healthcare providers seek more targeted approaches to cancer diagnosis and treatment.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation HubiScaleNascentDeveloping Advanced | |||||
| Cost-Sensitive RegioniScaleLowMedium High | |||||
| Regulatory EnvironmentiScaleRestrictiveNeutral Supportive | |||||
| Demand DriversiScaleWeakModerate Strong | |||||
| Development StageiScaleEmergingDeveloping Developed | |||||
| Adoption RateiScaleLowMedium High | |||||
| New Entrants / StartupsiScaleSparseModerate Dense | |||||
| Macro IndicatorsiScaleWeakStable Strong |
Key Country Insights
United States 🇺🇸
Precision Oncology TestingThe U.S. market prioritizes biomarker-based assays that support targeted therapy selection, tumor profiling, and increasingly personalized cancer management. Key priorities include expanding clinically actionable testing, integrating genomic information into treatment decisions, and improving access to assays that can guide therapy across diverse tumor types.
Germany 🇩🇪
Integrated Tumor ProfilingGermany emphasizes evidence-based molecular profiling within oncology pathways to support treatment selection and disease characterization. Priorities include broader clinical integration of biomarker assays, standardized testing workflows, and diagnostic capabilities that enable oncologists to identify actionable molecular alterations.
Japan 🇯🇵
Molecular Cancer StratificationJapan is focused on expanding molecular characterization of tumors to support precision oncology and treatment selection. Market priorities include comprehensive biomarker testing, integration of genomic findings into clinical workflows, and improving access to assays capable of identifying actionable alterations across major cancer indications.
South Korea 🇰🇷
Genomic Oncology IntegrationSouth Korea is strengthening the role of molecular diagnostics in cancer treatment decisions, particularly through genomic profiling and targeted biomarker testing. Priorities include broader use of clinically actionable assays, faster interpretation of tumor profiles, and integration of molecular results into oncology treatment pathways.
France 🇫🇷
Biomarker-Guided OncologyFrance prioritizes biomarker testing as a component of personalized cancer care, supporting treatment selection and molecular disease characterization. Market development centers on expanding access to validated assays, integrating results into multidisciplinary oncology decisions, and improving consistency of molecular testing across clinical settings.
Italy 🇮🇹
Expanding Precision DiagnosticsItaly's cancer biomarker assay market is shaped by increasing integration of molecular diagnostics into oncology care. Priorities include accessible tumor profiling, identification of actionable biomarkers, and stronger coordination between diagnostic laboratories and oncology teams to support personalized treatment decisions.
Cancer and Tumor Biomarker-based Assay Market Share (%), by End Use, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportEnd Use Segment Analysis: Hospitals and Cancer Centers (Largest & Fastest-Growing Segment)
The hospitals and cancer centers segment accounted for a 47% share of the cancer and tumor biomarker-based assay market in 2026 and is also expected to register the fastest growth over the forecast period. The segment's leading position is supported by the increasing integration of biomarker-based assays into routine cancer diagnosis, disease characterization, treatment selection, and therapy monitoring. Hospitals and specialized cancer centers typically have access to multidisciplinary oncology teams, advanced diagnostic infrastructure, and laboratory capabilities required to interpret complex biomarker information, making them important settings for the adoption of molecular and tumor-specific testing. The growing emphasis on personalized oncology is further strengthening demand, as clinicians increasingly rely on biomarker profiles to identify relevant therapeutic options and distinguish between patients with different disease characteristics. In addition, the expanding use of biomarker testing across screening, diagnosis, prognosis, and treatment monitoring is encouraging healthcare institutions to incorporate these assays more extensively into clinical workflows. Increasing cancer incidence, greater awareness of precision medicine, and continued improvements in assay sensitivity and specificity are expected to reinforce the role of hospitals and cancer centers as major end-use settings while supporting sustained segment expansion.
Cancer Type Segment Analysis: Breast Cancer (Largest & Fastest-Growing Segment)
The breast cancer segment accounted for a 25.3% share of the cancer and tumor biomarker-based assay market in 2026 and is also expected to experience the fastest growth during the forecast period. Its dominance is closely associated with the extensive use of biomarker-based testing to characterize breast tumors and guide clinical decision-making across different stages of disease management. Biomarker assays can support the identification of molecular characteristics that influence prognosis, treatment selection, and response assessment, increasing their relevance in breast cancer care. The growing adoption of personalized treatment strategies is encouraging clinicians to incorporate molecular and genomic information more consistently when evaluating patients, thereby expanding the role of biomarker-based assays beyond conventional diagnostic approaches. Rising awareness of early detection and the importance of individualized cancer management are also contributing to greater demand for advanced testing. Furthermore, continued research into tumor biology and the identification of additional clinically relevant biomarkers is broadening the potential applications of these assays in breast cancer, supporting both the segment's established market position and its continued growth.
Biomarker Type Segment Analysis: Genetic / Genomic Biomarkers (Largest & Fastest-Growing Segment)
The genetic / genomic biomarkers segment represents the largest and fastest-growing segment of the cancer and tumor biomarker-based assay market. Its strong position is driven by the increasing importance of molecular information in understanding tumor biology, identifying disease-associated alterations, and supporting more individualized cancer management. Genetic and genomic biomarker assays can provide insights into mutations, molecular alterations, and other characteristics that help clinicians classify tumors and inform therapeutic strategies, making them increasingly relevant across diagnosis, prognosis, treatment selection, and monitoring. The shift toward precision oncology is further accelerating demand for genomic information as healthcare providers seek to match patients with therapies according to the underlying molecular features of their tumors. At the same time, advances in molecular testing technologies are enabling the analysis of increasingly complex biomarker profiles, broadening the clinical applications of genetic and genomic assays. Growing research activity, expanding recognition of molecularly driven cancer treatment, and the increasing integration of genomic information into clinical workflows are expected to sustain the segment's rapid expansion.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| End Use | Hospitals and Cancer Centers, Diagnostic Laboratories, Others | Hospitals and Cancer Centers | Hospitals and Cancer Centers |
| Cancer Type | Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Ovarian Cancer, Others | Breast Cancer | Breast Cancer |
| Biomarker Type | Genetic / Genomic Biomarkers, Protein Biomarkers, Epigenetic Biomarkers, Others | Genetic / Genomic Biomarkers | Genetic / Genomic Biomarkers |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Competitive Landscape and Market Positioning
Analyst Perspective:
Clinical utility and market differentiation hinge on balancing high biomarker detection sensitivity with multiplex assay designs that offer complementary biological insights. While tissue-based testing remains foundational, liquid biopsies increasingly support less invasive, repeated molecular monitoring. Developers must pair these diagnostic methods with rigorous clinical validation and platform compatibility to ensure seamless integration into existing laboratory workflows and dependable patient care pathways.
Top players in the cancer and tumor biomarker-based assay market:
- Roche (Switzerland)
- Thermo Fisher Scientific (USA)
- Agilent Technologies (USA)
- Abbott (USA)
- Bio-Rad Laboratories (USA)
- Qiagen (Netherlands)
- Illumina (USA)
- Siemens Healthineers (Germany)
- Becton Dickinson (USA)
- Merck KGaA (Germany)
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Roche (Switzerland) | |||||||
| Thermo Fisher Scientific (USA) | |||||||
| Agilent Technologies (USA) | |||||||
| Abbott (USA) | |||||||
| Bio-Rad Laboratories (USA) | |||||||
| Qiagen (Netherlands) | |||||||
| Illumina (USA) | |||||||
| Siemens Healthineers (Germany) | |||||||
| Becton Dickinson (USA) | |||||||
| Merck KGaA (Germany) |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Exact Sciences Corp. | September 2025 | Exact Sciences Corp. introduced the Cancerguard test, a multi-cancer early detection blood assay available as a laboratory-developed test in the United States. This commercial release represents an expansion into early screening capabilities by analyzing diverse biomarker types to identify malignancies typically diagnosed at advanced stages. |
| Mainz Biomed | June 2025 | Mainz Biomed initiated the next development phase for PancAlert, a blood-based screening initiative targeting pancreatic cancer. This operational progression focuses on validating a novel biomarker panel to expand the company's early cancer detection portfolio. |
| Guardant Health | June 2025 | Guardant Health obtained United States Food and Drug Administration Breakthrough Device designation for its Shield Multi-Cancer test. The diagnostic offering identifies multiple tumor types through methylation signatures, demonstrating significant specificity metrics. |
| Roche | April 2025 | Roche committed an investment totaling USD 50 billion directed toward United States gene-therapy operational sites and artificial intelligence research facilities. This strategic capital allocation strengthens the company's long-term diagnostics footprint and technological infrastructure. |
| Labcorp | February 2025 | Labcorp commercially introduced Labcorp Plasma Complete, a circulating tumor DNA-based comprehensive genomic profiling assay designed for advanced solid tumors. This liquid biopsy solution facilitates detailed genomic analysis via routine blood draws to guide targeted oncology treatment decisions. |
| Illumina, Inc. | August 2024 | Illumina, Inc. secured United States Food and Drug Administration approval for its TruSight Oncology Comprehensive in vitro diagnostic test and initial companion diagnostic indications. The assay profiles over 500 genes to identify clinically actionable biomarkers, supporting personalized therapy selection and clinical trial enrollment for solid tumor patients. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Cancer and Tumor Biomarker-based Assay Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Testing Stage | Screening, Diagnosis, Treatment Selection, Disease Monitoring and Recurrence Detection |
| Sample Type | Tissue Samples, Blood Samples, Urine Samples, Other Body Fluids |
| Reimbursement Model | Public Insurance, Private Insurance, Self-Pay, Research and Institutional Funding |
Cancer and Tumor Biomarker-based Assay Market — Custom TOC
| Custom Chapter | Chapter Details |
|---|---|
| Clinical Adoption & Testing Pathways |
|
| Companion Diagnostic Commercialization |
|
| Biopharma Biomarker Demand Landscape |
|
Need a different cut of the data?
Request Custom ResearchFrequently Asked Questions
What is the market valuation of the cancer and tumor biomarker-based assay market?
What is the projected value of the cancer and tumor biomarker-based assay industry by 2036?
How is personalized medicine accelerating adoption of cancer biomarker-based assays?
How are assay innovations expanding the commercial application of tumor biomarker testing?
Which end-use segment dominates the cancer and tumor biomarker-based assay market?
Which cancer type segment is expected to grow fastest?
Why does North America lead the cancer and tumor biomarker-based assay market?
What is driving the rapid growth of biomarker-based cancer assays in Asia Pacific?
Who holds a significant market share in the cancer and tumor biomarker-based assay landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
This report was prepared by the Healthcare & Medical Devices Research Team at Fundamental Business Insights, a dedicated research group specializing in the global healthcare and medical technology industry. Our analysts continuously monitor advancements in medical technologies, clinical adoption trends, regulatory developments, reimbursement policies, healthcare infrastructure investments, competitive strategies, and evolving patient care requirements to deliver timely and reliable market intelligence. The research is developed using a structured methodology that combines primary discussions with healthcare stakeholders, company financial disclosures, regulatory publications, clinical literature, government healthcare databases, medical associations, and other authoritative secondary sources. Market estimates are validated through multiple research techniques, including top-down and bottom-up analysis, before undergoing an internal quality review to ensure accuracy, consistency, and methodological integrity prior to publication.
Delivery
Published
Available
Support
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook